Development of a Homogenous RSV Neutralisation Assay on the Mirrorball Fluorescence Cytometer
Application Note Jul 06, 2016
Human respiratory syncytial virus (RSV) is a syncytial virus that can cause serious respiratory tract infections, especially in infants and young children. To date there is no licensed vaccine against RSV infection and the only preventative treatment option is the neutralising anitbody palivizumab, which is given to high risk infants by passive administration. Therefore there is a strong drive to identify novel RSV-neutralising antibodies for therapeutic/preventative applications. Here we present the development and implementation of a simple RSV-neutralisation assay on TTP Labtech’s mirrorball fluorescence cytometer.